¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö : 2021-04-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö : 2021-04-09
±³À°ÀÏÀÚ : 2021-04-09
±³À°Àå¼Ò : ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : ´ëÇѳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö      
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : ´ëÇѳ»ºÐºñÇÐȸ
¿¬¶ôó : 02-2038-0072  
À̸ÞÀÏ : endo@endocrinology.or.kr      
±³À°Á¾·ù : ³»°ú, °¡Á¤ÀÇÇаú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 11 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í (Æò»ýȸ¿ø, Á¤È¸¿ø) Àü¹®ÀÇ / ÀüÀÓÀÇ / ±³¼ö / °³¿øÀÇ / ±âÃÊÀÇÇÐÀÚ: 100,000¿ø Àü°øÀÇ / ´ëÇпø»ý / ±ºÀÇ°ü / °øÁߺ¸°ÇÀÇ/ °£È£»ç / ¿µ¾ç»ç / ÀÇ·á±â»ç / ±âŸ: 50,000¿ø (ºñȸ¿ø) Àü¹®ÀÇ / ÀüÀÓÀÇ / ±³¼ö / °³¿øÀÇ / ±âÃÊÀÇÇÐÀÚ: 150,000 Àü°øÀÇ / ´ëÇпø»ý / ±ºÀÇ°ü / °øÁߺ¸°ÇÀÇ/ °£È£»ç / ¿µ¾ç»ç / ÀÇ·á±â»ç / ±âŸ: 70,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:00~09:20 LDL: PCSK9 inhibitor as the next statin?  ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:00~09:20 Disease of a thousand faces: Hyperparathyroidism  ÀÌÀ¯¹Ì(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:00~09:20 Epidemiology of acromegaly in Korea: Based on big data analysis  ¹Ú°æÇý(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:00~09:25 ÀÇ·á ±¤À½Çâ ¿µ»óÀÇ ¿ø¸®¿Í °©»ó¼± ¾Ï ¿µ»ó ÆÄÀÏ·µ ¿¬±¸ °á°ú  ±èöȫ(Æ÷Ç×°ø´ë âÀÇITÀ¶ÇÕ°øÇаú) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:20~09:40 TG: Is hypertriglyceridemia atherogenic?  ±è³²ÈÆ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:20~09:40 Is vitamin D supplementation safe and effective? Steady low dose vs intermittent high dose  °ø¼ºÇý(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:20~09:40 Autoimmune pituitary diseases  Yutaka Takahashi(Nara Medical University Japan) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:25~09:50 CXCL16, a regulator of tumor microenvironment in advanced thyroid cancer  Á¶¼±¿í(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:40~10:00 Does HDL-cholesterol paradox exist?  À̽Âȯ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:40~10:00 Clinical effectiveness of romosozumab and teriparatide  ±èÇÏ¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 09:40~10:00 Co-peptin: A new pituitary hormone?  ±èÁ¤Èñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 09:50~10:15 ÀΰøÁö´ÉÀ» ÀÌ¿ëÇÑ °©»ó¼±°áÀý Áø´ÜÀÇ ¹Ì·¡  ¹éÁ¤È¯(¿ï»êÀÇ´ë ¿µ»óÀÇÇаú) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 10:00~10:20 Lp(a): Lipoprotein(a) and CV risk : Are we there yet?  ±è»óÇö(¼­¿ïÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 10:00~10:30 Panel Discussion  ±è»ó¿Ï(¿Â¶óÀÎ Âü¿©)(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 10:00~10:30 Panel Discussion  ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 10:20~10:30 Panel Discussion  ±è»ó¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 10:50~11:20 Cellular senescence : Future translational viewpoint  °­¹«ÀÏ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 11:20~11:50 Olfactory Receptors & Olfactory Marker Protein signals in endocrine system  ÀÌÀºÁ÷(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 12:40~13:20 Precision medicine in diabetes  ¹Ú°æ¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 13:30~13:50 Epidemiology of adrenal cushing  ¾Èâȣ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 13:30~13:50 How dose COVID-19 affect osteoporosis and fracture?  ÇÏ¿ëÂù(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 2 (Live Channel 3) 13:30~13:50 ´ëÇѺñ¸¸ÇÐȸ ºñ¸¸ Áø·á Áöħ  ³²°¡Àº(°í·ÁÀÇ´ë °¡Á¤ÀÇÇаú) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 13:50~14:10 CT-based body composition biomarkers in hypercortisolism  È«³²±â(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 13:50~14:10 Acute sarcopenia secondary to COVID-19  ±è¹üÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 2 (Live Channel 3) 13:50~14:10 ºñ¸¸Ä¡·áÀÇ ÃÖ½ÅÁö°ß  ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 14:10~14:30 Introduction to new medical drugs for adrenal diseases  ¹ÚÁ¤È¯(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 14:10~14:30 Can vitamin D protect against COVID-19?  ÃÖÇѼ®(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 2 (Live Channel 3) 14:10~14:30 Saxenda (Liraglutide 3.0 mg) real world study of Korea  ÀÓ¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ¿¢½ºÆ÷Ȧ (Live Channel 1) 14:30~15:00 Panel Discussion  ±¸À¯Á¤(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 1 (Live Channel 2) 14:30~15:00 Panel Discussion  ±è°æ¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 09ÀÏ ±×·£µåȦ 2 (Live Channel 3) 14:30~15:00 Panel Discussion  °­ÁöÇö(°Ç¾çÀÇ´ë °¡Á¤ÀÇÇаú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ ¹× Çп¬»ê ½ÉÆ÷Áö¾ö : 2021-04-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021³â ´ëÇÑÃéÀå´ãµµÇÐȸ Ãá°èÇмú´ëȸ : 2021-04-09
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ : 2021-04-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 3 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 3 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 107 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 9 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 23 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 10 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 5 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 4 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 1 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 5 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 9 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 6 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷